Insider · CIK 0001217439
FINNEY ELISHA W
director
Files at MTD (METTLER TOLEDO INTERNATIONAL INC/), VTRS (Viatris Inc). First filing Nov 13, 2024, latest Nov 13, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $100k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Side | Company | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 30Weak | sell | MTD METTLER TOLEDO INTERNATIONAL INC/ | $100k | 76 | -24% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 6, 2025 | VTRS Viatris Inc | AGrant or award Restricted Stock Unitsderivative | +23,660 | $0.00 | $0 | 23,660 | Mar 10, 2025 |
| Mar 4, 2025 | VTRS Viatris Inc | MOption exercise Common Stock | +18,204 | $0.00 | $0 | 37,059 | Mar 5, 2025 |
| Mar 4, 2025 | VTRS Viatris Inc | MOption exercise Common Stock | +773 | $0.00 | $0 | 37,832 | Mar 5, 2025 |
| Mar 4, 2025 | VTRS Viatris Inc | MOption exercise Restricted Stock Unitsderivative | -18,204 | $0.00 | $0 | 0 | Mar 5, 2025 |
| Mar 4, 2025 | VTRS Viatris Inc | MOption exercise Dividend Equivalent Unitsderivative | -773 | $0.00 | $0 | 0 | Mar 5, 2025 |
| Nov 12, 2024 | MTD METTLER TOLEDO INTERNATIONAL INC/ | AGrant or award Common Stock, par value $0.01 per share | +71 | $0.00 | $0 | 311 | Nov 14, 2024 |
| Nov 12, 2024 | MTD METTLER TOLEDO INTERNATIONAL INC/ | AGrant or award Stock Option (right to buy)derivative | +182 | $0.00 | $0 | 182 | Nov 14, 2024 |
| Nov 11, 2024 | MTD METTLER TOLEDO INTERNATIONAL INC/ | SOpen-market sale Common Stock, par value $0.01 per share | -76 | $1,311.75 | $100k | 240 | Nov 13, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.